Site Editor
Thomas Flaig, MD
Thomas Flaig, MD
Posted: Wednesday, March 29, 2023
Wenpeng Ni, PhD, of Southern Medical University, Zongshan, China, and colleagues studied the potential role of abnormal proline-rich protein 11 (PRR11) expression in bladder urothelial carcinoma. Their study, published in Scientific Reports, used various online databases and bioinformatics methods to collect RNA sequences and clinical information from 411 bladder urothelial carcinoma projects.
“Our findings suggested a significant prognostic value of PRR11 and a potentially promising target for immunotherapeutic strategies in bladder urothelial carcinoma,” the investigators concluded.
The researchers found that PRR11 is highly expressed in bladder urothelial carcinoma and is associated with worse patient outcomes. Additionally, there was found to be a significant correlation between PRR11 expression and tumor mutational burden and immune cell infiltration in bladder urothelial carcinoma.
These findings suggest that PRR11 may be a potential marker for bladder urothelial carcinoma patient assessment and risk stratification, and its role in the tumor microenvironment and targeted therapy should be further investigated. Overall, the study provides insight into the potential prognostic and therapeutic implications of PRR11 expression in bladder urothelial carcinoma.
Disclosure: The study authors reported no conflicts of interest.
JNCCN Spotlights
Resources
For your Patients
